199 related articles for article (PubMed ID: 38056898)
1. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells.
Wu L; Liu X; Lei J; Zhang N; Zhao H; Zhang J; Deng H; Li Y
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056898
[TBL] [Abstract][Full Text] [Related]
2. FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape.
Wu L; Xu Y; Zhao H; Zhou Y; Chen Y; Yang S; Lei J; Zhang J; Wang J; Wu Y; Li Y
Theranostics; 2022; 12(2):842-858. PubMed ID: 34976216
[No Abstract] [Full Text] [Related]
3. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
4. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
[TBL] [Abstract][Full Text] [Related]
5. Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer.
Zhu Y; Zhang L; Zha H; Yang F; Hu C; Chen L; Guo B; Zhu B
Int J Biol Sci; 2017; 13(6):804-814. PubMed ID: 28656005
[TBL] [Abstract][Full Text] [Related]
6. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment.
Liu BQ; Bao ZY; Zhu JY; Liu H
Oncol Lett; 2021 Jan; 21(1):47. PubMed ID: 33281958
[TBL] [Abstract][Full Text] [Related]
8. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
9. FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
Zhao Z; Qin J; Qian Y; Huang C; Liu X; Wang N; Li L; Chao Y; Tan B; Zhang N; Qian M; Li D; Liu M; Du B
J Hematol Oncol; 2024 Feb; 17(1):9. PubMed ID: 38402237
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Zheng Y; Tian X; Wang T; Xia X; Cao F; Tian J; Xu P; Ma J; Xu H; Wang S
Mol Cancer; 2019 Mar; 18(1):61. PubMed ID: 30925926
[TBL] [Abstract][Full Text] [Related]
11. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
12. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression.
Xie Z; Ikegami T; Ago Y; Okada N; Tachibana M
Oncoimmunology; 2020; 9(1):1734268. PubMed ID: 32158627
[TBL] [Abstract][Full Text] [Related]
15. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
[TBL] [Abstract][Full Text] [Related]
16. IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Lim HX; Choi S; Cho D; Kim TS
Immunol Cell Biol; 2017 Jan; 95(1):99-107. PubMed ID: 27507556
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
18. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
19. Modified method for differentiation of myeloid-derived suppressor cells
Zhou H; Xie Z; Morikawa N; Sakurai F; Mizuguchi H; Okuzaki D; Okada N; Tachibana M
Biochem Biophys Rep; 2023 Mar; 33():101416. PubMed ID: 36605123
[TBL] [Abstract][Full Text] [Related]
20. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
